1. Putative molecular signatures for the imaging of prostate cancer.
   Yang S Y, Adelstein J, Kassis AI.
   Expert Rev Mol Diagn 2010 Jan;10(1):65-74 Pubmed
2. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.
   Prasad PD, Stanton JA, Assinder SJ.
   Cell Tissue Res [Epub ahead of print] Pubmed
3. Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.
   Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.
   Oncogene 28, 4344–4352 (10 December 2009) | doi:10 1038/onc 2009 286 Pubmed
4. Gene networks in Drosophila melanogaster: integrating experimental data to predict gene function.
   Costello JC, Dalkilic MM, Beason SM, Gehlhausen JR, Patwardhan R, Middha S, Eads BD, Andrews JR.
   Genome Biol 2009;10(9):R97 Epub 2009 Sep 16 Pubmed
5. Unraveling the Signal-Transduction Networks in Cancer Metastasis.
   Guangxu Jin, Kemi Cui, Xiaobo Zhou, Wong S. 
   Signal Processing Magazine, IEEE 2009 Sep;26(5):129-132 Link
6. Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective.
   Huang S, Ernberg I, Kauffman S.
   Semin Cell Dev Biol 2009 Sep;20(7):869-76 Epub 2009 Jul 10 Pubmed
7. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
   Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.
   J Clin Invest 2009 Sep;119(9):2678-90 doi: 10 1172/JCI37815 Epub 2009 Aug 24 Pubmed
8. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.
   McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL.
   J Clin Invest 2009 Sep;119(9):2663-77 doi: 10 1172/JCI37691 Epub 2009 Aug 24 Pubmed
9. RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease.
   Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.
   Neoplasia 2009 Sep;11(9):956-63 Pubmed
10. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.
    Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A.
    Oncogene 2009 Sep 17;28(37):3296-306 Epub 2009 Jul 27 Pubmed
11. The IKK2/NF-kappa B pathway suppresses MYC-induced lymphomagenesis.
    Klapproth K, Sander S, Marinkovic D, Baumann B, Wirth T.
    Blood 2009 Sep 17;114(12):2448-58 Epub 2009 Jul 23 Pubmed
12. DNMT1 and DNMT3B Modulate Distinct Polycomb-Mediated Histone Modifications in Colon Cancer.
    Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C, Robertson KD.
    Cancer Res 2009 Sep 15;69(18):7412-21 Epub 2009 Sep 1 Pubmed
13. Gene Expression Profile of Primary Prostate Epithelial and Stromal Cells in Response to Sulforaphane or Iberin Exposure.
    Chambers KF, Bacon JR, Kemsley EK, Mills RD, Ball RY, Mithen RF, Traka MH.
    Prostate 2009 Sep 15;69(13):1411-21 Pubmed
14. Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-alpha and NF-kappa b are key components of the innate immune response to the pathogen.
    Dozmorov M, Wu W, Chakrabarty K, Booth JL, Hurst RE, Coggeshall KM, Metcalf JP.
    BMC Infect Dis 2009 Sep 10;9:152 Pubmed
15. Identification of a Protein, G0S2, That Lacks Bcl-2 Homology Domains and Interacts with and Antagonizes Bcl-2.
    Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, Teodoro JG, Green MR.
    Cancer Res 2009 Sep 1;69(17):6782-9 Epub 2009 Aug 25 Pubmed
16. Comprehensive Analysis of Conditioned Media from Ovarian Cancer Cell Lines Identifies Novel Candidate Markers of Epithelial Ovarian Cancer.
    Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP.
    J Proteome Res 2009 Oct;8(10):4705-13 Pubmed
17. Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays.
    Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI.
    Mol Cell Proteomics 2009 Oct;8(10):2382-95 Epub 2009 Jul 28 Pubmed
18. HAX-1: A multifunctional protein with emerging roles in human disease.
    Fadeel B, Grzybowska E.
    Biochim Biophys Acta 2009 Oct;1790(10):1139-48 Epub 2009 Jun 12 Pubmed
19. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.
    Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G.
    Nat Struct Mol Biol 2009 Oct;16(10):1086-93 Epub 2009 Sep 27 Pubmed
20. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
    Montañez-Wiscovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.
    Oncogene 2009 Oct 15;28(41):3608-18 Epub 2009 Aug 3 Pubmed
21. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.
    Blood 2009 Oct 15;114(16):3361-2 Pubmed
22. A Role for the Clock Gene Per1 in Prostate Cancer.
    Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP.
    Cancer Res 2009 Oct 1;69(19):7619-25 Epub 2009 Sep 14 Pubmed
23. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.
    Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP.
    Int J Cancer 2009 Oct 1;125(7):1613-21 Pubmed
24. Correlating Global Gene Regulation to Angiogenesis in the Developing Chick Extra-Embryonic Vascular System.
    Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A, Hagedorn M.
    PLoS One 2009 Nov 17;4(11):e7856 Pubmed
25. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation.
    Devlin AH, Thompson P, Robson T, McKeown SR.
    Mol Carcinog 2009 Nov 11 [Epub ahead of print] Pubmed
26. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival.
    Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND.
    Breast Cancer Res 2009 Nov 10;11(6):R81 [Epub ahead of print] Pubmed
27. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias.
    Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL.
    Int J Cancer 2009 Nov 1;125(9):2219-28 Pubmed
28. Selenoprotein P regulation by the glucocorticoid receptor.
    Rock C, Moos PJ.
    Biometals 2009 Jun 10 [Epub ahead of print] Pubmed
29. A c-Myc regulatory subnetwork from human transposable element sequences.
    Wang J, Bowen NJ, Chang L, Mariño-Ramírez H, Jordan IK.
    Mol Biosyst 2009 Jul 21 [Epub ahead of print] Pubmed
30. Computational Identification of a p38(SAPK)-Regulated Transcription Factor Network Required for Tumor Cell Quiescence.
    Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA.
    Cancer Res 2009 Jul 15;69(14):5664-72 Epub 2009 Jul 7 Pubmed
31. Gene expression profiling of archival tongue squamous cell carcinomas provides sub-classification based on DNA repair genes.
    Rentoft M, Laurell G, Coates PJ, Sjöström B, Nylander K.
    Int J Oncol 2009 Dec;35(6):1321-30 Pubmed
32. Translocations in epithelial cancers.
    Brenner JC, Chinnaiyan AM.
    Biochim Biophys Acta 2009 Dec;1796(2):201-15 Epub 2009 May 4 Pubmed
33. Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System.
    Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R.
    Cancer Prev Res (Phila Pa) 2009 Aug;2(8):702-11 Epub 2009 Jul 28 Pubmed
34. Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic mice.
    Siam R, Harada R, Cadieux C, Battat R, Vadnais C, Nepveu A.
    Mol Cancer 2009 Aug 5;8:60 Pubmed
35. Tumor Suppression by Phospholipase C-beta 3 via SHP-1-Mediated Dephosphorylation of Stat5.
    Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T.
    Cancer Cell 2009 Aug 4;16(2):161-71 Pubmed
36. Oncomine meta-analysis of breast cancer microarray data identifies upregulation of NRF-1 expression in human breast carcinoma.
    Kunkle, B., Q. Felty, F. Trevino, D. Roy
    18th World IMACS / MODSIM Congress, Cairns, Australia 13-17 July 2009
37. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.
    DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C.
    Cancer Res. 2009 Jul 1;69(13):5364-73. Epub 2009 Jun 23. Pubmed
38. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
    Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Fang F, Mellinghoff IK, Chan TA.
    Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9435-40. Epub 2009 May 28. Pubmed
39. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.
    Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, Kimura K, Yanagisawa J.
    Oncogene. 2009 Jun 8. [Epub ahead of print] Pubmed
40. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.
    Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J.
    BMC Cancer. 2009 Jun 7;9:173. Pubmed
41. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors.
    Hussain S, Zhang Y, Galardy PJ.
    Cell Cycle. 2009 Jun 1;8(11):1688-97. Pubmed
42. Rab7 activation by growth factor withdrawal contributes to the induction of apoptosis.
    Romero Rosales K, Peralta ER, Guenther GG, Wong SY, Edinger AL.
    Mol Biol Cell. 2009 Jun;20(12):2831-40. Epub 2009 Apr 22. Pubmed
43. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis.
    Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Geradts J.
    Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1899-903. Pubmed
44. Embryonic stem cell markers expression in cancers.
    Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B.
    Biochem Biophys Res Commun. 2009 May 29;383(2):157-62. Epub 2009 Mar 4. Pubmed
45. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.
    Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC.
    Cancer Res. 2009 May 15;69(10):4388-97. Epub 2009 Apr 28. Pubmed
46. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.
    Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A.
    J Natl Cancer Inst. 2009 May 6;101(9):663-77. Epub 2009 Apr 28. Pubmed
47. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.
    Mannefeld M, Klassen E, Gaubatz S.
    Cancer Res. 2009 May 1;69(9):4073-80. Epub 2009 Apr 21. Pubmed
48. Proepithelin is an autocrine growth factor for bladder cancer.
    Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.
    Carcinogenesis. 2009 May;30(5):861-8. Epub 2009 Feb 23. Pubmed
49. Artemin is oncogenic for human mammary carcinoma cells.
    Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE.
    Oncogene. 2009 May 14;28(19):2034-45. Epub 2009 Apr 13. Pubmed
50. A compendium of potential biomarkers of pancreatic cancer.
    Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, Marimuthu A, Kashyap M, Vizza RF, Mayer RJ, Decaprio JA, Srivastava S, Hanash SM, Hruban RH, Pandey A.
    PLoS Med. 2009 Apr 7;6(4):e1000046. Epub 2009 Apr 7. Pubmed
51. Learning therapeutic lessons from metastasis suppressor proteins.
    Smith SC, Theodorescu D.
    Nat Rev Cancer. 2009 Apr;9(4):253-64. Epub 2009 Feb 26. Pubmed
52. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.
    Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise I, Dupuy AJ, Collier LS, Powers S, Oberg AL, Asmann YW, Thibodeau SN, Tessarollo L, Copeland NG, Jenkins NA, Cormier RT, Largaespada DA.
    Science. 2009 Mar 27;323(5922):1747-50. Epub 2009 Feb 26. Pubmed
53. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J, Veyrune JL, De Vos J, Klein B.
    BMC Cancer. 2009 Mar 16;9:83. Pubmed
54. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.
    Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A.
    Clin Cancer Res. 2009 Mar 15;15(6):2058-66. Epub 2009 Feb 24. Pubmed
55. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.
    Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A.
    Am J Pathol. 2009 Mar;174(3):1037-47. Epub 2009 Jan 29. Pubmed
56. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.
    Ojalvo LS, King W, Cox D, Pollard JW.
    Am J Pathol. 2009 Mar;174(3):1048-64. Epub 2009 Feb 13. Pubmed
57. Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation.
    Billottet, C; Banerjee, L; Vanhaesebroeck, B; Khwaja, A
    Cancer Res. 2009 Feb 1;69(3):1027-36. Epub 2009 Jan 27. Pubmed
58. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.
    Arencibia, JM; Martin, S; Perez-Rodriguez, FJ; Bonnin, A
    Int J Oncol. 2009 Feb;34(2):457-63. Pubmed
59. Characterization of EVL-I as a protein kinase D substrate.
    Janssens, K; De Kimpe, L; Balsamo, M; Vandoninck, S; Vandenheede, JR; Gertler, F; Van Lint, J
    Cell Signal. 2009 Feb;21(2):282-92. Epub 2008 Oct 29. Pubmed
60. The Ral GTPase pathway in metastatic bladder cancer: Key mediator and therapeutic target.
    Smith, SC; Theodorescu, D
    Urol Oncol. 2009 Jan-Feb;27(1):42-7. Pubmed
61. Modulated expression of WFDC1 during carcinogenesis and cellular senescence.
    Madar, S; Brosh, R; Buganim, Y; Ezra, O; Goldstein, I; Solomon, H; Kogan, I; Goldfinger, N; Klocker, H; Rotter, V
    Carcinogenesis. 2009 Jan;30(1):20-7. Epub 2008 Oct 8. Pubmed
62. DEK Proto-Oncogene Expression Interferes with the Normal Epithelial Differentiation Program.
    Wise-Draper, TM; Morreale, RJ; Morris, TA; Mintz-Cole, RA; Hoskii, EE; Balsitis, SJ; Husseinzadeh, N; Witte, DP; Wikenheiser-Brokamp, KA; Lambert, PF; Wells, SI
    Am J Pathol. 2009 Jan;174(1):71-81. Epub 2008 Nov 26. Pubmed
63. Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach.
    Wilson BJ.
    J Carcinog. 2008;7:6. Pubmed
64. Molecular and prognostic markers in prostate cancer - A study of cell-cycle regulators, angiogenesis and candidate markers - Introduction.
    Halvorsen, OJ
    APMIS Suppl. 2008;(123):5-62. Pubmed
65. Arylamine N-acetyltransferases: From structure to function.
    Sim, E; Walters, K; Boukouvala, S
    Drug Metab Rev. 2008;40(3):479-510. Pubmed
66. MMSET is overexpressed in cancers: Link with tumor aggressiveness.
    Kassambara A, Klein B, Moreaux J.
    Biochem Biophys Res Commun. 2008 Dec 30. [Epub ahead of print] Pubmed
67. Confirmation of Gene Expression - Based Prediction of Survival in Non-Small Cell Lung Cancer.
    Guo, NL; Wan, YW; Tosun, K; Lin, H; Msiska, Z; Flynn, DC; Remick, SC; Vallyathan, V; Dowlati, A; Shi, X; Castranova, V; Beer, DG; Qian, Y
    Clin Cancer Res. 2008 Dec 15;14(24):8213-20. Pubmed
68. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
    Tshuikina, M; Jernberg-Wiklund, H; Nilsson, K; Oberg, F
    Exp Hematol. 2008 Dec;36(12):1673-1681. Epub 2008 Oct 15. Pubmed
69. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4.
    Murn J, Alibert O, Wu N, Tendil S, Gidrol X.
    J Exp Med. 2008 Dec 22;205(13):3091-103. Epub 2008 Dec 15. Pubmed
70. A functional Notch-survivin gene signature in basal breast cancer.
    Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh CC, Altieri DC.
    Breast Cancer Res. 2008;10(6):R97. Epub 2008 Nov 24. Pubmed
71. Tissue Inhibitor of Metalloproteinases-4. The road less traveled.
    Melendez-Zajgla, J; Del Pozo, L; Ceballos, G; Maldonado, V
    Mol Cancer. 2008 Nov 21;7:85. Pubmed
72. Identifying differential correlation in gene/pathway combinations.
    Braun, R; Cope, L; Parmigiani, G
    BMC Bioinformatics. 2008 Nov 18;9:488. Pubmed
73. The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1-Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer.
    Arnoldussen, YJ; Lorenzo, PI; Pretorius, ME; Waehre, H; Risberg, B; Maelandsmo, GM; Danielsen, HE; Saatcioglu, F
    Cancer Res. 2008 Nov 15;68(22):9255-64. Pubmed
74. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.
    Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS.
    Breast Cancer Res. 2008;10(6):R94. Epub 2008 Nov 13. Pubmed
75. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.
    Yang Y, Iyer LK, Adelstein SJ, Kassis AI.
    PLoS ONE. 2008;3(11):e3661. Epub 2008 Nov 6. Pubmed
76. DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity.
    Yegnasubramanian, S; Haffner, MC; Zhang, YG; Gurel, B; Cornish, TC; Wu, ZJ; Irizarry, RA; Morgan, J; Hicks, J; DeWeese, TL; Isaacs, WB; Bova, GS; De Marzo, AM; Nelson, WG
    Cancer Res. 2008 Nov 1;68(21):8954-67. Pubmed
77. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
    Engelsen, IB; Stefansson, IM; Akslen, LA; Salvesen, HB
    Am J Obstet Gynecol. 2008 Nov;199(5):543.e1-7. Epub 2008 Jul 3. Pubmed
78. Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients.
    Findeisen, P; Rockel, M; Nees, M; Roder, C; Kienle, P; Doeberitz, MV; Kalthoff, H; Neumaier, M
    Int J Oncol. 2008 Nov;33(5):1001-10. Pubmed
79. Notch1 is an effector of Akt and hypoxia in melanoma development.
    Bedogni, B; Warneke, JA; Nickoloff, BJ; Giaccia, AJ; Powell, MB
    J Clin Invest. 2008 Nov;118(11):3660-70. Epub 2008 Oct 16. Pubmed
80. Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer.
    Varambally, S; Laxman, B; Mehra, R; Cao, Q; Dhanasekaran, S; Tomlins, SA; Granger, J; Vellaichamy, A; Sreekumar, A; Yu, JJ; Gu, WJ; Shen, RL; Ghosh, D; Wright, LM; Kladney, RD; Kuefer, R; Rubin, MA; Fimmel, CJ; Chinnaiyan, AM
    Neoplasia. 2008 Nov;10(11):1285-94. Pubmed
81. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.
    Clin Cancer Res. 2008 Nov 15;14(22):7452-60. Pubmed
82. The network biomarker discovery in prostate cancer from both genomics and proteomics levels.
    Jin GX, Zhou XB, Cui KM, et al.
    Conference Information: 2nd International Symposium on Optimization and Systems Biology, OCT 31-NOV 03, 2008 Lijiang, PEOPLES R CHINASource: OPTIMIZATION AND SYSTEMS BIOLOGY, PROCEEDINGS Book Series: Lecture Notes in Operations Research Volume: 9 Pages: 144-151 Published: 2008
83. FYN is overexpressed in human prostate cancer.
    Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R.
    BJU Int. 2008 Oct 16. [Epub ahead of print] Pubmed
84. The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer.
    Nolan, ME; Aranda, V; Lee, S; Lakshmi, B; Basu, S; Allred, DC; Muthuswamy, SK
    Cancer Res. 2008 Oct 15;68(20):8201-9. Pubmed
85. The correlation between cellular size and protein expression levels - Normalization for global protein profiling.
    Lundberg, E; Gry, M; Oksvold, P; Kononen, J; Andersson-Svahn, H; Ponten, F; Uhlen, M; Asplund, A
    J Proteomics. 2008 Oct 7;71(4):448-60. Epub 2008 Jul 5. Pubmed
86. Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.
    Kang, YK; Schiff, R; Ko, L; Wang, T; Tsai, SY; Tsai, MJ; O’Malley, BW
    Cancer Res. 2008 Oct 1;68(19):7887-96. Pubmed
87. Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo.
    Smith, EL; Schuchman, EH
    Br J Cancer. 2008 Sep 16;99(6):939-48. Pubmed
88. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
    Kristiansen, G; Fritzsche, FR; Wassermann, K; Jager, C; Toelle, A; Lein, M; Stephan, C; Jung, K; Pilarsky, C; Dietel, M; Moch, H
    Br J Cancer. 2008 Sep 16;99(6):939-48. Pubmed
89. Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets.
    Ramasamy, A; Mondry, A; Holmes, CC; Altman, DG
    PLoS Med. 2008 Sep 2;5(9):e184. [Epub ahead of print] Pubmed
90. Studying chromosome instability in the mouse.
    Foijer, F; Draviam, VM; Sorger, PK
    Biochim Biophys Acta. 2008 Sep;1786(1):73-82. Epub 2008 Jul 26. Pubmed
91. RCS1, a substrate of APC/C, controls the metaphase to anaphase transition.
    Zhao, WM; Coppinger, JA; Seki, A; Cheng, XL; Yates, JR; Fang, GW
    Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13415-20. Epub 2008 Aug 29. Pubmed
92. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.
    Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.
    Cancer Immunol Immunother. 2008, Sep;57(9):1357-65. Epub 2008 Feb 12. Pubmed
93. GATA-3 as a Marker of Hormone Response in Breast Cancer.
    Fang SH, Chen Y, Weigel RJ.
    J Surg Res. 2008 Aug 26. [Epub ahead of print] Pubmed
94. Wilms’ tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han, YQ; Yang, L; Suarez-Saiz, F; San-Marina, S; Cui, J; Minden, MD
    Mol Cancer Res. 2008 Aug;6(8):1347-55. Pubmed
95. Membrane-associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated cancer/testis antigen.
    Foell, JL; Hesse, M; Volkmer, I; Schmiedel, BJ; Neumann, I; Staege, MS
    Pediatr Blood Cancer. 2008 Aug;51(2):228-34. Pubmed
96. Meta-analysis of SUMO1.
    Wilson BJ.
    BMC Res Notes. 2008 Jul 31;1:60. Pubmed
97. ATF6 alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.
    Schewe, DM; Aguirre-Ghiso, JA
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10519-24. Epub 2008 Jul 23. Pubmed
98. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.
    Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML
    Oncogene. 2008 Jul 17;27(31):4353-62. Epub 2008 Mar 31. Pubmed
99. Acetylcholinesterase supports anchorage independence in colon cancer.
    Syed, M; Fenoglio-Preiser, C; Skau, KA; Weber, GF
    Clin Exp Metastasis. 2008;25(7):787-98. Epub 2008 Jul 9. Pubmed
100. Recurrent gene fusions in prostate cancer.
     Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.
     Nat Rev Cancer. 2008 Jul;8(7):497-511. Epub 2008 Jun 19. Pubmed
101. Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity.
     Link, KA; Balasubramaniam, S; Sharma, A; Comstock, CES; Godoy-Tundidor, S; Powers, N; Cao, KH; Haelens, A; Claessens, F; Revelo, MP; Knudsen, KE
     Cancer Res. 2008 Jun 15;68(12):4551-8. Pubmed
102. Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation.
     Ghosh D, Chinnaiyan AM.
     Biostatistics. 2008 Jun 6. Pubmed
103. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.
     Wilson BJ, Giguère V.
     Mol Cancer. 2008 Jun 4;7:49. Pubmed
104. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
     Setlur, SR; Mertz, KD; Hoshida, Y; Demichelis, F; Lupien, M; Perner, S; Sboner, A; Pawitan, Y; Andren, O; Johnson, LA; Tang, J; Adami, HO; Calza, S; Chinnaiyan, AM; Rhodes, D; Tomlins, S; Fall, K; Mucci, LA; Kantoff, PW; Stampfer, MJ; Andersson, SO; Varenhorst, E; Johansson, JE; Brown, M; Golub, TR; Rubin, MA
     J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. Epub 2008 May 27. Pubmed
105. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.
     Ganesan, K; Ivanova, T; Wu, YH; Rajasegaran, V; Wu, J; Lee, MH; Yu, K; Rha, SY; Chung, HC; Ylstra, B; Meijer, G; Lian, KO; Grabsch, H; Tan, P
     Cancer Res. 2008 Jun 1;68(11):4277-86. Pubmed
106. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.
     Chan, TA; Glockner, S; Yi, JM; Chen, W; Van Neste, L; Cope, L; Herman, JG; Velculescu, V; Schuebel, KE; Ahuja, N; Baylin, SB
     PLoS Med. 2008 May 27;5(5):e114. Pubmed
107. Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
     Lusa, L; Peissel, B; Manoukian, S; Marchesi, E; Radice, P; Pierotti, MA; Gariboldi, M
     J Natl Cancer Inst. 2008 May 21;100(10):752-3; author reply 753-4. Epub 2008 May 13. Pubmed
108. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
     Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
     Cancer Res. 2008 May 15;68(10):3584-90. Pubmed
109. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.
     Meyer, KB; Maia, AT; O’Reilly, M; Teschendorff, AE; Chin, SF; Caldas, C; Ponder, BAJ
     PLoS Biol. 2008 May 6;6(5):e108. Pubmed
110. The discovery and application of gene fusions in prostate cancer.
     Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM.
     BJU Int. 2008 Apr 16. Pubmed
111. Elevated tRNA(i)(Met) synthesis can drive cell proliferation and oncogenic transformation.
     Marshall, L; Kenneth, NS; White, RJ
     Cell. 2008 Apr 4;133(1):78-89. Pubmed
112. Amplification and overexpression of PPFIAI, a putative IIq13 invasion suppressor gene, in head and neck squamous cell carcinoma.
     Tan, KD; Zhu, Y; Tan, HK; Rajasegaran, V; Aggarwal, A; Wu, J; Wu, HY; Hwang, J; Lim, DTH; Soo, KC; Tan, P
     Genes Chromosomes Cancer. 2008 Apr;47(4):353-62. Pubmed
113. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.
     Butt, AJ; Sergio, CM; Inman, CK; Anderson, LR; McNeil, CM; Russell, AJ; Nousch, M; Preiss, T; Biankin, AV; Sutherland, RL; Musgrove, EA
     Breast Cancer Res. 2008;10(2):R28. Epub 2008 Mar 29. Pubmed
114. Predicting cancer involvement of genes from heterogeneous data.
     Aragues, R; Sander, C; Oliva, B
     BMC Bioinformatics. 2008 Mar 27;9:172. Pubmed
115. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression.
     Zhou, Z; Ran, YL; Hu, H; Pan, J; Li, ZF; Chen, LZ; Sun, LC; Peng, L; Zhao, XL; Yu, L; Sun, LX; Yang, ZH
     Clin Exp Metastasis. 2008;25(5):537-48. Epub 2008 Mar 26. Pubmed
116. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.
     McCabe, CD; Spyropoulos, DD; Martin, D; Moreno, CS
     Cancer Res. 2008 Mar 15;68(6):1988-96. Pubmed
117. Tumor cell dependence on Ran-GTP-directed mitosis.
     Xia, F; Lee, CW; Altieri, DC
     Cancer Res. 2008 Mar 15;68(6):1826-33. Pubmed
118. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.
     Li, RS; Guo, Y; Han, BM; Yan, XW; Utleg, AG; Li, W; Tu, LC; Wang, J; Hood, L; Xia, SJ; Lin, BY
     Proteomics. 2008 Mar 7;2(4):543-555 Link
119. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.
     Beitzinger, M; Hofmann, L; Oswald, C; Beinoraviciute-Kellner, R; Sauer, M; Griesmann, H; Bretz, AC; Burek, C; Rosenwald, A; Stiewe, T
     EMBO J. 2008 Mar 5;27(5):792-803. Epub 2008 Jan 31. Pubmed
120. Gene expression profiling of non-small-cell lung cancer.
     Lacroix, L; Commo, F; Soria, JC
     Expert Rev Mol Diagn. 2008 Mar;8(2):167-78. Pubmed
121. CXCL5 promotes prostate cancer progression.
     Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA.
     Neoplasia. 2008 Mar;10(3):244-54. Pubmed
122. Humoral response profiling reveals pathways to prostate cancer progression.
     Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A.
     Mol Cell Proteomics. 2008 Mar;7(3):600-11. Epub 2007 Dec 11.< Pubmed
123. Hsp60 regulation of tumor cell apoptosis.
     Ghosh, JC; Dohi, T; Kang, BH; Altieri, DC
     J Biol Chem. 2008 Feb 22;283(8):5188-94. Epub 2007 Dec 17. Pubmed
124. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
     Sorensen, KD; Borre, M; Orntoft, TF; Dyrskjot, L; Torring, N
     Int J Cancer. 2008 Feb 1;122(3):509-19. Pubmed
125. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.
     Ruiz-Vela, A; Aggarwal, M; de la Cueva, P; Treda, C; Herreros, B; Martfn-Perez, D; Dominguez, O; Piris, MA
     Blood. 2008 Feb 1;111(3):1665-76. Epub 2007 Nov 21. Pubmed
126. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
     Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.
     Cancer Res. 2008 Feb 1;68(3):645-9. Pubmed
127. CD200: a putative therapeutic target in cancer.
     Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.
     Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22. Epub 2007 Dec 4. Pubmed
128. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.
     Gordon, KJ; Dong, M; Chislock, EM; Fields, TA; Blobe, GC
     Carcinogenesis. 2008 Feb;29(2):252-62. Epub 2007 Nov 13. Pubmed
129. CLEAR-test: Combining inference for differential expression and variability in microarray data analysis.
     Valls, J; Grau, M; Sole, X; Hernandez, P; Montaner, D; Dopazo, J; Peinado, MA; Capella, G; Moreno, V; Pujana, MA
     J Biomed Inform. 2008 Feb;41(1):33-45. Epub 2007 May 17. Pubmed
130. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
     Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.
     Neoplasia. 2008 Feb;10(2):177-88. Pubmed
131. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
     Smith DD, Saetrom P, Snove O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.
     BMC Bioinformatics. 2008 Jan 28;9(1):63 Pubmed
132. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
     Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.
     Cancer Res. 2008 Jan 1;68(1):73-80. Pubmed
133. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.
     Chinnaiyan, AM; Lippman, ME; Yu, JJ; Yu, J; Cordero, KE; Johnson, MD; Ghosh, D; Rae, JM
     Neoplasia. 2008 Jan;10(1):79-88. Pubmed
134. DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact.
     Cao, ZF; Huett, A; Kuballa, P; Giallourakis, C; Xavier, RJ
     Cell Signal. 2008 Jan;20(1):73-82. Epub 2007 Sep 12. Pubmed
135. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.
     Wong, SY; Crowley, D; Bronson, RT; Hynes, RO
     Clin Exp Metastasis. 2008;25(2):109-18. Epub 2007 Dec 5. Pubmed
136. Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease.
     Vanpoucke, G; Orr, B; Grace, OC; Chan, R; Ashley, GR; Williams, K; Franco, OE; Hayward, S; Thomson, AA
     Genome Biol. 2007;8(10):R213. Pubmed
137. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.
     Blenkiron, C; Goldstein, LD; Thorne, NP; Spiteri, I; Chin, SF; Dunning, MJ; Barbosa-Morais, NL; Teschendorff, AE; Green, AR; Ellis, IO; Tavare, S; Caldas, C; Miska, EA
     Genome Biol. 2007;8(10):R214. Pubmed
138. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
     van Duin, M; van Marion, R; Vissers, KJ; Hop, WCJ; Dinjens, WNM; Tilanus, HW; Siersema, PD; van Dekken, H
     Cytogenet Genome Res. 2007;118(2-4):130-7. Pubmed
139. A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.
     Esseghir, S; Todd, SK; Hunt, T; Poulsom, R; Plaza-Menacho, I; Reis-Filho, JS; Isacke, CM
     Cancer Res. 2007 Dec 15;67(24):11732-41. Pubmed
140. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.
     Xiang, Y; Zhu, Z; Han, G; Ye, X; Xu, B; Peng, Z; Ma, Y; Yu, Y; Lin, H; Chen, AP; Chen, CD
     Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19226-31. Epub 2007 Nov 28. Pubmed
141. A mechanism misregulating p27 in tumors discovered in a functional genomic screen.
     Garrett-Engele, CM; Tasch, MA; Hwang, HC; Fero, ML; Perlmutter, RM; Clurman, BE; Roberts, JM
     PLoS Genet. 2007 Dec;3(12):e219. Pubmed
142. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
     Wu, MH; Soler, DR; Abba, MC; Nunez, MI; Baer, R; Hatzis, C; Llombart-Cussac, A; Llombart-Bosch, A; Aldaz, CM
     Mol Cancer Res. 2007 Dec;5(12):1285-95. Pubmed
143. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin.
     Leong, KG; Niessen, K; Kulic, I; Raouf, A; Eaves, C; Pollet, I; Karsan, A
     J Exp Med. 2007 Nov 26;204(12):2935-48. Epub 2007 Nov 5. Pubmed
144. Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?
     Sharifi, N; Lechleider, RJ; Farrar, WL
     J Mol Endocrinol. 2007 Nov;39(5):329-32. Pubmed
145. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis.
     Wilson BJ, Giguère V.
     BMC Genomics. 2007 Nov 15;8:419. Pubmed
146. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.
     Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM.
     Cancer Cell. 2007 Nov;12(5):419-31. Pubmed
147. Understanding systemic sclerosis through gene expression profiling.
     Pendergrass, SA; Whitfield, ML; Gardner, H
     Curr Opin Rheumatol. 2007 Nov;19(6):561-7. Pubmed
148. Meta- and gene set analysis of stomach cancer gene expression data.
     Kim, S; Kim, J; Lee, H; Noh, S; Song, K; Cho, J; Jeong, H; Kim, WH; Yeom, Y; Kim, N; Kim, S; Yoo, H; Kim, YS
     Mol Cells. 2007 Oct 31;24(2):200-9. Pubmed
149. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion.
     Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB
     Oncogene. 2007 Oct 18;26(48):6885-95. Epub 2007 May 21. Pubmed
150. JMJD3 is a histone H3K27 demethylase.
     Xiang, Y; Zhu, ZQ; Han, G; Lin, HQ; Xu, LY; Chen, CD
     Cell Res. 2007 Oct;17(10):850-7. Pubmed
151. Claudin-7 immunohistochemistry in renal tumors - A candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
     Hornsby, CD; Cohen, C; Amin, MB; Picken, MM; Lawson, D; Yin-Goen, QQ; Young, AN
     Arch Pathol Lab Med. 2007 Oct;131(10):1541-6. Pubmed
152. A latent variable approach for meta-analysis of gene expression data from multiple microarray experiments.
     Choi H, Shen R, Chinnaiyan AM, Ghosh D.
     BMC Bioinformatics. 2007 Sep 27;8:364. Pubmed
153. Identification of five human novel genes associated with cell proliferation by cell-based screening from an expressed cDNA ORF library.
     Ma, X; Wang, X; Gao, X; Wang, L; Lu, Y; Gao, P; Deng, WW; Yu, P; Ma, JJ; Guo, JH; Cheng, HL; Zhang, CY; Shi, TP; Ma, DL
     Life Sci. 2007 Sep 15;81(14):1141-51. Epub 2007 Aug 17. Pubmed
154. Integrative analysis of genomic aberrations associated with prostate cancer progression.
     Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
     Cancer Res. 2007 Sep 1;67(17):8229-39. Pubmed
155. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
     Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.
     Cancer Res. 2007 Sep 1;67(17):7991-5. Pubmed
156. Thymosin beta-NB is the human isoform of rat thymosin beta 15.
     Banyard, J; Hutchinson, LM; Zetter, BR
     Ann N Y Acad Sci. 2007 Sep;1112:286-96. Epub 2007 Jun 13. Pubmed
157. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
     Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M.
     Mol Cell. 2007 Aug 3;27(3):380-92. Pubmed
158. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character.
     Niemantsverdriet M, Wagner K, Visser M, Backendorf C.
     Oncogene. 2008 Feb 21;27(9):1315-9. Epub 2007 Aug 20. Pubmed
159. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior.
     Degen M, Brellier F, Kain R, et al.
     Cancer Research 67 (19): 9169-9179 Oct 1 2007 Pubmed
160. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status.
     Abba MC, Sun H, Hawkins KA, et al.
     Molecular Cancer Research 5 (9): 881-890 Sep 2007 Pubmed
161. Integrative genomic analysis of phosphatidylinositol 3 ‘-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer.
     Zhang L, Huang J, Yang N, et al.
     Clinical Cancer Research 13 (18): 5314-5321 Part 1 Sep 15 2007 Pubmed
162. The la autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
     Al-Ejeh F, Darby JM, Brown MP
     Clinical Cancer Research 13 (18): 5509s-5518s Part 2 Suppl. S Sep 15 2007 Pubmed
163. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
     Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
     Nature. 2007 Aug 2;448(7153):595-9. Pubmed
164. The lethal phenotype of cancer: the molecular basis of death due to malignancy.
     Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ.
     CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41. Review. Erratum in: CA Cancer J Clin. 2007 Nov-Dec;57(6):380. Pubmed
165. UTRN on chromosome 6q24 is mutated in multiple tumors.
     Li Y, Huang J, Zhao YL, et al.
     Oncogene 26 (42): 6220-6228 Sep 13 2007 Pubmed
166. Expression of interleukin-13 receptor alpha 2 in glioblastoma multiforme: Implications for targeted therapies.
     Jarboe JS, Johnson KR, Choi Y, et al.
     Cancer Research 67 (17): 7983-7986 Sep 1 2007 Pubmed
167. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.
     O’Neill CF, Urs S, Cinelli C, et al.
     American Journal of Pathology 171 (3): 1023-1036 Sep 2007 Pubmed
168. Mining gene expression profiles: expression signatures as cancer phenotypes.
     Joseph R. Nevins and Anil Potti
     Nature Reviews/Genetics. 2007 Aug vol 8:601 NPG
169. Protein 4.1B suppresses prostate cancer progression and metastasis.
     Wong SY, Haack H, Kissil JL, et al.
     Proceedings of The National Academy of Sciences of The United States of America 104 (31): 12784-12789 Jul 31 2007 Pubmed
170. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.
     Wang QB, Li W, Liu XS, et al.
     Molecular Cell 27 (3): 380-392 Aug 3 2007 Pubmed
171. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.
     Tedesco D, Zhang JH, Trinh L, et al.
     Neoplasia 9 (7): 601-u4 Jul 2007 Pubmed
172. Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse.
     Franklin MR, Moos PJ, El-Sayed WM, et al.
     Chemico-Biological Interactions 168 (3): 211-220 Jul 20 2007 Pubmed
173. Evidence for systems-level molecular mechanisms of tumorigenesis.
     Hernandez P, Huerta-Cepas J, Montaner D, et al.
     BMC Genomics 8: Art. No. 185 Jun 20 2007 Pubmed
174. Expression of Ral GTPases, their effectors, and activators in human bladder cancer.
     Smith SC, Oxford G, Baras AS, et al.
     Clinical Cancer Research 13 (13): 3803-3813 Jul 1 2007 Pubmed
175. Large-scale integration of cancer microarray data identifies a robust common cancer signature.
     Xu L, Geman D, Winslow RL
     BMC Bioinformatics 8: Art. No. 275 Jul 30 2007 Pubmed
176. Characterization of protein-interaction networks in tumors.
     Platzer A, Perco P, Lukas A, et al.
     BMC Bioinformatics 8: Art. No. 224 Jun 27 2007 Pubmed
177. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.
     Paulson KE, Rieger-Christ K, McDevitt NA, et al.
     Cancer Research 67 (13): 6136-6145 Jul 1 2007 Pubmed
178. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.
     Lange K, Kammerer M, Hegi ME, et al.
     Cancer Research 67 (13): 6163-6173 Jul 1 2007 Pubmed
179. Metastasis-associated protein 1 transgenic mice: A new model of spontaneous B-Cell lymphornas.
     Bagheri-Yarmand R, Balasenthil S, Gururaj AE, et al.
     Cancer Research 67 (15): 7062-7067 Aug 1 2007 Pubmed
180. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
     Kim B, Lee HJ, Choi HY, et al.
     Cancer Research 67 (15): 7431-7438 Aug 1 2007 Pubmed
181. DGEM - A Microarray gene expression database for primary human disease tissues.
     Xia YN, Campen A, Rigsby D, et al.
     Molecular Diagnosis & Therapy 11 (3): 145-149 2007 Pubmed
182. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
     Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
     Am J Surg Pathol. 2007 Jun;31(6):882-8. Pubmed
183. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
     Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
     J Pathol. 2007 May;212(1):91-101. Pubmed
184. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
     Warnat P, Oberthuer A, Fischer M, et al.
     BMC Cancer 7: Art. No. 89 May 25 2007 Pubmed
185. CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit.
     Seki A, Fang GW
     Journal of Biological Chemistry 282 (20): 15103-15113 May 18 2007 Pubmed
186. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.
     Abba MC, Fabris VT, Hu YH, et al.
     Cancer Research 67 (9): 4104-4112 May 1 2007 Pubmed
187. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME.
     Finocchiaro G, Mancuso FM, Cittaro D, et al.
     Nucleic Acids Research 35 (7): 2343-2355 Apr 2007 Pubmed
188. CCR2 expression correlates with prostate cancer progression.
     Lu Y, Cai Z, Xiao GZ, et al.
     Jrl of Cellular Biochemistry 101 (3): 676-685 JUN 1 2007 Pubmed
189. Mass spectrometry-based “omics” technologies in cancer diagnostics.
     Zhang XW, Wei D, Yap Y, et al.
     Mass Spectrometry Rvws 26 (3): 403-431 MAY-JUN 2007 Pubmed
190. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.
     Ma WB, Stafford LJ, Li DL, et al.
     Jrl of Cellular Biochemistry 100 (6): 1376-1386 APR 15 2007 Pubmed
191. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma.
     Chen GA, Wang XJ, Yu JJ, et al.
     Cancer Research 67 (7): 3461-3467 APR 1 2007 Pubmed
192. 5-aza-2 ‘-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.
     Zorn CS, Wojno KJ, McCabe MT, et al.
     Clinical Cancer Research 13 (7): 2136-2143 APR 1 2007 Pubmed
193. Feature selection and molecular classification of cancer using genetic programming.
     Yu JJ, Yu JD, Almal AA, et al.
     Neoplasia 9 (4): 292-U16 APR 2007 Pubmed
194. Role of the chromobox protein CBX7 in lymphomagenesis.
     Scott CL, Gil J, Hernando E, et al.
     Proceedings of The National Academy of Sciences of The United States of America 104 (13): 5389-5394 MAR 27 2007 Pubmed
195. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.
     Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.
     Mod Pathol. 2007 May;20(5):538-44. Epub 2007 Mar 2. Pubmed
196. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor.
     Stabile H, Mitola S, Moroni E, et al.
     Blood 109 (5): 1834-1840 MAR 1 2007 Pubmed
197. LRIG-inhibitors of growth factor signalling - double-edged swords in human cancer?
     Hedman H, Henriksson R
     European Journal of Cancer 43 (4): 676-682 MAR 2007 Pubmed
198. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis.
     Sadanandam A, Varney ML, Kinarsky L, et al.
     Omics-a Jrl of Integrative Biology 11 (1): 41-57 MAR 2007 Pubmed
199. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
     Rody A, Holtrich U, Gaetje R, et al.
     Clinical Cancer Research 13 (4): 1115-1122 FEB 15 2007 Pubmed
200. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
     Podar K, Raab MS, Tonon G, et al.
     Cancer Research 67 (4): 1680-1688 FEB 15 2007 Pubmed
201. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.
     Lin KY, Lu D, Hung CF, et al.
     Cancer Research 67 (4): 1832-1841 FEB 15 2007 Pubmed
202. TGFBR3 loss and consequences in prostate cancer.
     Sharifi N, Hurt EM, Kawasaki BT, et al.
     Prostate 67 (3): 301-311 FEB 15 2007 Pubmed
203. DNA microarray technology in toxicogenomics of aquatic models: Methods and applications.
     Ju ZL, Wells MC, Walter RB
     Comparative Biochemistry & Physiology C-toxicology & Pharmacology 145 (1): 5-14 Sp. Iss. SI FEB 2007 Pubmed
204. From bytes to bedside: Data integration and computational biology for translational cancer research.
     Mathew JP, Taylor BS, Bader GD, et al.
     Plos Computational Biology 3 (2): 153-163 FEB 2007 Pubmed
205. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
     Kharas, MG; Yusuf, I; Scarfone, VM; Yang, VW; Segre, JA; Huettner, CS; Fruman, DA
     Blood. 2007 Jan 15;109(2):747-55. Epub 2006 Sep 5. Pubmed
206. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.
     Tompkins, VS; Hagen, J; Frazier, AA; Lushnikova, T; Fitzgerald, MP; di Tommaso, A; Ladeveze, V; Domann, FE; Eischen, CM; Quelle, DE
     J Biol Chem. 2007 Jan 12;282(2):1322-33. Epub 2006 Nov 16. Pubmed
207. Computational prediction of cancer-gene function.
     Pingzhao Hu, Gary Bader, Dennis A. Wigle and Andrew Emili
     Nature Reviews/Cancer. 2007 Jan; vol 7:23 NPG
208. Chromosomal deletions in bladder cancer: Shutting down pathways.
     Abraham R, Pagano F, Gomella LG, et al.
     Frontiers In Bioscience 12: 826-838 JAN 1 2007 Pubmed
209. Innovation - The Connectivity Map: a new tool for biomedical research.
     Lamb, J
     Nat Rev Cancer. 2007 Jan;7(1):54-60. Pubmed
210. Computational prediction of cancer-gene function.
     Pingzhao Hu, Gary Bader, Dennis A. Wigle and Andrew Emili
     Nature Reviews/Cancer. 2007 Jan; vol 7:23 Pubmed
211. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.
     Sotillo R, Hernando E, Diaz-Rodriguez E, et al.
     Cancer Cell 11 (1): 9-23 JAN 2007 Pubmed
212. Targeting cell cycle kinases for cancer therapy.
     de Carcer G, de Castro IP, Malumbres M
     Current Medicinal Chemistry 14 (9): 969-985 2007 Pubmed
213. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.
     Assou S, Le Carrour T, Tondeur S, et al.
     Stem Cells 25 (4): 961-973 2007 Pubmed
214. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
     Yen L, Cao ZW, Wu XL, et al.
     Cancer Research 2006 Dec; 66 (23): 11279-11286. Pubmed
215. Resources for integrative systems biology: from data through databases to networks and dynamic system models.
     Ng A, Bursteinas B, Gao QO, et al.
     Briefings in Bioinformatics 2006 Dec; 7 (4): 318-330. Pubmed
216. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
     Chan KYY, Lai PBS, Squire JA, et al.
     Modern Pathology 2006 Dec.; 19 (12): 1546-1554. Pubmed
217. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2 ‘,5 ‘-oligoadenylate synthetase from prostate cancer cells.
     Molinaro, RJ; Jha, BK; Malathi, K; Varambally, S; Chinnaiyan, AM; Silverman, RH
     Nucleic Acids Res. 2006;34(22):6684-95. Epub 2006 Dec 1. Pubmed
218. The HBP1 transcriptional repressor participates in RAS-induced premature senescence.
     Zhang XW, Kim J, Ruthazer R, et al.
     Molecular an Cellular Biology 2006 Nov.; 26 (22): 8252-8266. Pubmed
219. A Novel Role of Myosin VI in Human Prostate Cancer.
     Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J
     American J Pathology. 2006 Nov; 169(5):1843-54. Pubmed
220. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
     Rubin MA, Chinnaiyan AM.
     Laboratory Inestigation 2006 Nov; 86 (11): 1099-1102. Pubmed
221. Evidence of recurrent gene fusions in common epithelial tumors.
     Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
     Trends in Molecular Medicine 2006 Nov.; 12 (11): 529-536. Pubmed
222. Strategies for plasma proteomic profiling of cancers.
     Omenn, GS
     Proteomics. 2006 Oct;6(20):5662-73. Pubmed
223. Comparative microarray analysis.
     Larsson O, Wennmalm K, Sandberg R
     Omics-A Journal of Integrative Biology 2006 Sep; 10 (3): 381-397. Pubmed
224. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis.
     Zhao WM, Seki A, Fang GW.
     Molecular Biology of the Cell 2006 Sep; 17 (9): 3881-3896. Pubmed
225. Differential proteomic alterations between localised and metastatic prostate cancer.
     Taylor BS, Varambally S, Chinnaiyan AM.
     British Journal of Cancer 2006 Aug; 95 (4): 425-430. Pubmed
226. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
     Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K.
     Nature. 2006 Jul 20;442(7100):307-11. Pubmed
227. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue.
     Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA.
     Arch Pathol Lab Med. 2006 Jul;130(7):989-96. Pubmed
228. CCL2 is a potent regulator of prostate cancer cell migration and proliferation.
     Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ.
     Neoplasia. 2006 Jul; 8(7):578-86. Pubmed
229. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.
     Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y.
     Clinical Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54. Pubmed
230. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.
     Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.
     J Cell Science. 2006 Jun 15;119(Pt 12):2583-91. Pubmed
231. Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression.
     Zhang L, Yoder SJ, Enkemann SA.
     BMC Genomics 2006 Jun; 7: Art. No. 153. Pubmed
232. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
     Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.
     Neoplasia. 2006 Jun;8(6):465-9. Pubmed
233. Identification of genes expressed differentially in an in vitro human lung carcinogenesis model.
     Lacroix L, Feng G, Lotan R.
     Cancer Biology & Therapy 2006 Jun; 5 (6): 665-673. Pubmed
234. Cross-platform classification in microarray-based leukemia diagnostics.
     Nilsson, B; Andersson, A; Johansson, M; Fioretos, T
     Haematologica. 2006 Jun;91(6):821-4. Pubmed
235. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
     Kaposi-Novak, P; Lee, JS; Gomez-Quiroz, L; Coulouarn, C; Factor, VM; Thorgeirsson, SS
     J Clin Invest. 2006 Jun;116(6):1582-95. Epub 2006 May 18. Pubmed
236. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
     Collard RL, Harya NS, Monzon FA, Maier CE, O’Keefe DS.
     Prostate. 2006 May 15;66(7):687-95 Pubmed
237. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
     Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O’Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL, Coukos G.
     Cancer Res. 2006 May 1;66(9):4627-35 Pubmed
238. Functional screening for proapoptotic genes by reverse transfection cell array technology.
     Mannherz O, Mertens D, Hahn M, Lichter P.
     Genomics. 2006 May;87(5):665-72. Pubmed
239. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.
     Li, Z; Szabolcs, M; Terwilliger, JD; Efstratiadis, A
     Carcinogenesis. 2006 May;27(5):1054-67. Epub 2006 Jan 9. Pubmed
240. Prostate-specific antigen, high-molecular-weight cytokeratin (Clone 34 beta E12), and/or p63 - An optimal lmmunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
     Kunju, LP; Mehra, R; Snyder, M; Shah, RB
     Am J Clin Pathol. 2006 May;125(5):675-81. Pubmed
241. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.
     Kuefer, R; Day, KC; Kleer, CG; Sabel, MS; Hofer, MD; Varambally, S; Zorn, CS; Chinnaiyan, AM; Rubin, MA; Day, ML
     Neoplasia. 2006 Apr;8(4):319-29. Pubmed
242. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
     Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N.
     Cancer Res. 66, 2584-2591, Mar 1, 2006. Pubmed
243. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.
     O’Donnell, KA; Yu, DN; Zeller, KI; Kim, JW; Racke, F; Thomas-Tikhonenko, A; Dang, CV
     Mol Cell Biol. 2006 Mar;26(6):2373-86. Pubmed
244. ETS-TMPRSS2 fusion gene products in prostate cancer.
     Ahlers, CM; Figg, WD
     Cancer Biol Ther. 2006 Mar;5(3):254-5. Epub 2006 Mar 13. Pubmed
245. Low pH induces co-ordinate regulation of gene expression in oesophageal cells.
     Duggan SP, Gallagher WM, Fox EJ, Abdel-Latif MM, Reynolds JV, Kelleher D.
     Carcinogenesis. 2006 Feb;27(2):319-27. Pubmed
246. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
     Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY.
     Clinical Cancer Res. 2006 Feb . 15;12(4):1128-36. Pubmed
247. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
     Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
     Clinical Cancer Res. 2006 Jan 1;12(1):131-8. Pubmed
248. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.
     Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M.
     Oncogene. 2006 Jan 19;25(3):359-69. Pubmed
249. Defining aggressive prostate cancer using a 12-gene model.
     Bismar TA, Demichelis F, Riva A, et al.
     Neoplasia 2006 Jan; 8 (1): 59-68. Pubmed
250. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
     Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A.
     Tumor Biol. 2006;27(4):211-20. Pubmed
251. Integrative biology of prostate cancer progression.
     Tomlins SA, Rubin MA, Chinnaiyan AM
     Annual Review of Pathology-Mechanisms of Disease 1 (1): 243-271 2006. Pubmed
252. Molecular analysis of minimally invasive follicular carcinomas by gene profiling.
     Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey TJ
     Surgery. 2005 Dec;138(6):1042-8. Pubmed
253. A review of the past, present, and future directions of neoplasia.
     Rehemtulla, A., and Ross, B. D.
     Neoplasia 2005 Dec; 7(12), 1039-1046. Pubmed
254. The octamer binding transcription factor Oct-1 is a stress sensor.
     Tantin D, Schild-Poulter C, Wang V, Hache RJ, Sharp PA.
     Cancer Res. 2005 Dec 1;65(23):10750-8. Pubmed
255. Two different global gene expression profiles in cancer cell lines established from etiologically different oral carcinomas.
     Ruutu, M., Johansson, B., Grenman, R., Syrjanen, S.
     Oncol Rep 2005 Dec; 14(6), 1511-1517. Pubmed
256. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
     Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG.
     Cancer Res. 2005 Dec 15; 65(24):11259-64. Pubmed
257. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.
     Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A. M., Ferguson, D. O., Merajver, S. D., Kleer, C. G.
     Neoplasia 2005 Dec. 7(11), 1011-1019. Pubmed
258. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer.
     Hu M, Shivdasani RA.
     Cancer Res. 2005 Oct 1;65(19):8715-22. Pubmed
259. Identification of MMP-15 as an anti-apoptotic factor in cancer cells.
     Abraham R, Schafer J, Rothe M, Bange J, Knyazev P, Ullrich A.
     J Biol Chem. 2005 Oct 7;280(40):34123-32. Pubmed
260. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists.
     Cahan, P., Ahmad, A. M., Burke, H., Fu, S., Lai, Y., Florea, L., Dharker, N., Kobrinski, T., Kale, P., and McCaffrey, T. A.
     Gene 2005 Oct; 360, 78-82. Pubmed
261. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival.
     Bergom C, Gao C, Newman PJ.
     Leuk Lymphoma. 2005 Oct; 46(10):1409-21. Pubmed
262. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data.
     Xu, L., Tan, A. C., Naiman, D. Q., Geman, D., and Winslow, R. L.
     Bioinformatics 2005 Oct; 21, 3905-3911. Pubmed
263. Autoantibody signatures in prostate cancer.
     Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM.
     NEJM. 2005 Sep.; (2): 1224-1235. Pubmed
264. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
     Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET.
     Cancer Res. 2005 Sep 1;65(17):7554-60. Pubmed
265. Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.
     Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Sauermann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guilleaume B, Wellenreuther R, Pepperkok R, Sultmann H, Poustka A, Wiemann S.
     Cancer Res. 2005 Sep; 65(17):7733-42. Pubmed
266. Emerging issues of the expression profiling technologies for the study of gynecologic cancer.
     Pappa, K. I., and Anagnou, N. P.
     Am J Obstet Gynecol 2005 Sep.;. 193, 908-918. Pubmed
267. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
     Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA.
     J Pathol. 2005 Sep ; 207(1):14-9. Pubmed
268. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?
     Hashimoto, Y., Skacel, M., and Adams, J. C.
     Int J Biochem Cell Biol 2005 Sep; 37, 1787-1804. Pubmed
269. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
     Laganiere, J., Deblois, G., Lefebvre, C., Bataille, A. R., Robert, F., and Giguere, V.
     Proc Natl Acad Sci USA 2005 Aug; 102,11651-11656. Pubmed
270. GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data.
     Statnikov, A., Tsamardinos, I., Dosbayev, Y., and Aliferis, C. F.
     Int J Med Inform 2005 Aug; 74, 491-503. Pubmed
271. Storing, linking, and mining microarray databases using SRS.
     Veldhoven, A., de Lange, D., Smid, M., de Jager, V., Kors, J. A., and Jenster, G.
     BMC Bioinformatics 2005 Jul; 6, 192. Pubmed
272. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.
     Alpy, F., and Tomasetto, C.
     J Cell Science 2005 Jul; 118, 2791-2801. Pubmed
273. High-resolution genomic profiles of human lung cancer.
     Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.
     Proc Natl Acad Sci U S A. 2005 Jul; 102(27):9625-30. Pubmed
274. Microarray-based classification of diffuse large B-cell lymphoma.
     Poulsen CB, Borup R, Nielsen FC, Borregaard N, Hansen M, Gronbaek K, Moller MB, Ralfkiaer E.
     European J Haematology. 2005 Jun; 74(6):453-65. Pubmed
275. A genetic screen for candidate tumor suppressors identifies REST.
     Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al.
     Cell 2005 Jun; 121, 837-848. Pubmed
276. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
     Haruki, N., Kawaguchi, K. S., Eichenberger, S., Massion, P. P., Olson, S., Gonzalez, A., Carbone, D. P., and Dang, T. P.
     Cancer Research 2005 May; 65, 3555-3561. Pubmed
277. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.
     Bergmann, S., Royer-Pokora, B., Fietze, E., Jurchott, K., Hildebrandt, B., Trost, D., Leenders, F., Claude, J. C., Theuring, F., Bargou, R., et al.
     Cancer Research 2005 May; 65, 4078-4087. Pubmed
278. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
     Mayeur, G. L., Kung, W. J., Martinez, A., Izumiya, C., Chen, D. J., and Kung, H. J.
     J Biol Chem 2005 Mar; 280, 10827-10833. Pubmed
279. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
     Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.
     Cancer Research. 2005 Feb 15; 65(4):1479-88. Pubmed
280. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
     Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.
     Oncogene. 2005 Feb 3;24(6):1053-65. Pubmed
281. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.
     Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.
     FASEB J. 2005 Feb;19(2):243-5. Pubmed
282. A database for tracking toxicogenomic samples and procedures.
     Bao, W., Schmid, J. E., Goetz, A. K., Ren, H., and Dix, D. J.
     Reproductive Toxicology 2005 Jan.-Feb.; 19, 411-419. Pubmed
283. L2L: a simple tool for discovering the hidden significance in microarray expression data.
     Newman, J. C., and Weiner, A. M.
     Genome Biol 2005. 6(9), R81. Pubmed
284. Common and contrasting genomic profiles among the major human lung cancer subtypes
     Tonon, G; Brennan, C; Protopopov, A; Maulik, G; Feng, B; Zhang, Y; Khatry, DB; You, MJ; Aguirre, AJ; Martin, ES; Yang, Z; Ji, H; Chin, L; Wong, KK; DePinho, RA
     Cold Spring Harb Symp Quant Biol. 2005;70:11-24. Pubmed
285. The tumor protein D52 family: many pieces, many puzzles.
     Boutros, R., Fanayan, S., Shehata, M., and Byrne, J. A.
     Biochem Biophys Res Commun 2004 Dec; 325, 1115-1121. Pubmed
286. Splicing factors are differentially expressed in tumors.
     Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ.
     Genet Mol Res. 2004 Dec 30;3(4):512-20. Pubmed
287. Adrogen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
     Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.
     Cancer Res. 2004 Dec; 64(24):9209-16. Pubmed
288. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies.
     Shi, L., Tong, W., Goodsaid, F., Frueh, F. W., Fang, H., Han, T., Fuscoe, J., and Casciano, D. A.
     Expert Rev Mol Diagnostics 2004 Nov; 4, 761-777. Pubmed
289. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells.
     Guzey M, Luo J, Getzenberg RH.
     J Cell Biochem. 2004 Oct 1;93(2):271-85. Pubmed
290. JAGGED1 expression is associated with prostate cancer metastasis and recurrence.
     Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC.
     Cancer Res. 2004 Oct; 64(19):6854-7. Pubmed
291. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.
     Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.
     Oncogene 2004 Aug.; 23 (39): 6621-6629. Pubmed
292. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.
     Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.
     Hum Mol Genet. 2004 Jul;13(13):1303-13. Pubmed
293. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
     Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM.
     Cancer Res. 2004 Jan 1;64(1):55-63. Pubmed

Download a complete list of references.